Aug 10, 2023 / 04:30PM GMT
John Newman - Canaccord Genuity Group Inc. - Analyst
Good afternoon, everyone, and thank you for joining us at the 43rd Annual Canaccord Genuity Growth Conference. I'm John Newman, one of the biotech analysts here at Canaccord based in New York.
We're very excited to have Faron with us today. And joining us are the CEO, Markku Jalkanen; and the CMO, Marie-Louise Fjällskog. So welcome to you both.
Marie-Louise Fjällskog - Faron Pharmaceuticals Oy - Chief Medical Officer
Thank you.
Questions and Answers:
John Newman - Canaccord Genuity Group Inc. - AnalystI'm going to take a seat over here now. So thanks for joining us. I'm wondering if we could start by talking about your lead assets, excuse me, bexmarilimab. I believe this targets something called Clever-1. Could you first talk to us about the importance of this target, biologically?
Markku Jalkanen - Faron Pharmaceuticals Oy - CEO & Executive Director
Absolutely.